Arginine, nitric oxide and endothelial function;Arginina, óxido nítrico y función endotelial

Ars Pharmaceutica

Volumn 45, Issue 4, 2004, Pages 303-317

  Martinez Augustin O ^a   Sanchez De Medina F ^a  

^a UNIVERSITY OF GRANADA   (Spain)

Author keywords

Arginine; Endothelial function; Nitric oxide

Indexed keywords

ARGININE; NITRIC OXIDE;

BINDING AFFINITY; CELL FUNCTION; DIETARY INTAKE; ENDOTHELIUM CELL; ENZYME MECHANISM; HUMAN; MOLECULAR DYNAMICS; REVIEW; TISSUE;

EID: 24944510851     PISSN: 00042927     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (20)

1. Barbul A. Arginine: biochemistry, physiology, and therapeutic implications. Journal of Parenteral and Enteral Nutrition 1986;10:227-238
2. Suchner U, Heyland DK, Peter K. Immune-modulatory actions of argnine in the critically ill. British Journal of Nutrition 2002;87(Suppl.1): S121-S132
3. Moncada S, Palmer RMJ,Higgs EA. Nitric oxide: physiology, patophysiology, and pharmacology. Pharmacol Rev 1991;43:109-42
4. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-126
5. Kinlay S, Ganz P. Role of endothelial dysfunction in coronary artery disease and implications for therapy. Am J Cardiol 1997;80: 11-I-16-I
6. De Caterina R. Endothelial dysfunction: common denomiators in vascular disease. Curr Opin Lipidol 2000;11:9-23
7. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J 2001;357:593-615
8. Kritchevsky D. Dietary protein, cholesterol and atherosclerosis. J Nutr 1995;125(Suppl):589S-593S
9. Appel LJ. The effects of protein intake on blood pressure and cardiovascular disease. Curr Opin Lipidol 2003;14:55-59
10. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-5
11. Böger RH, Bode-Böger SM, Szuba A, Chan JR, Tangphao O, Blaschke TF et al. Asymmetric dimethylarginine: a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998;98(18):1842-7
12. Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 2000;20:2032-37
13. Böger RH, Lentz SR, Bode-Böger SM, Knapp HR, Haynes WG. Elevation of asymmetricial dimethylarginine may mediate endothelial dysfunction during experimentl hyperhomocyst(e)inaemia in humans. Clin Sci (Lond) 2001;100 (2):161-7
14. Stamler JS, Hausladen A. Oxidative modifications in nitrosative stress. Nature Struct Biol 1998;5:247-249
15. Brown AA, Hu FB. Dietary modulation of endothelial function: implications for cardiovascular disease. Am J Clin Nutr 2001;73:673-686
16. Chen J, Kuhlencordt P, Urano F, Ichinose H, Astern J, Huang PL. Effects of chronic treatment with L-arginine on atherosclerosis in apoE knockout and apoE/inducible NO synthase double-knockout mice, Arterioscler Thromb Vasc Biol 2003;23:97-103
17. Zoccali C, Bode-Böger SM, Mallamaci F, Benedetto FA, Tripepi G, Malatino LS et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001;358:2113-17
18. Wu G, Meininger CJ. Regulation of nitric oxide synthesis by dietary factors. Annu Rev Nutr 2002;22:61-86
19. Selley ML. Increased concentrations of homocysteine and asymmetrical dimethilarginine and decreased concentrations of nitric oxide in the plasma of patients with Alzheimer's disease. Neurobiology of Aging 2003;24:903-907
20. Ohtsuka Y, Nakaya J. Effect of oral administration of L-arginine on senile dementia. Am J Med 2000;108(5):439.